Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.